RU2004108902A -
METHOD FOR TREATING FREEZERS OF III-IV DEGREES
- Google Patents
METHOD FOR TREATING FREEZERS OF III-IV DEGREES
Download PDF
Info
Publication number
RU2004108902A
RU2004108902ARU2004108902/14ARU2004108902ARU2004108902ARU 2004108902 ARU2004108902 ARU 2004108902ARU 2004108902/14 ARU2004108902/14 ARU 2004108902/14ARU 2004108902 ARU2004108902 ARU 2004108902ARU 2004108902 ARU2004108902 ARU 2004108902A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ков Евгений Юрьевич Б (RU), Евгений Юрьевич БяковfiledCriticalков Евгений Юрьевич Б (RU)
Priority to RU2004108902/14ApriorityCriticalpatent/RU2004108902A/en
Publication of RU2004108902ApublicationCriticalpatent/RU2004108902A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Claims (1)
Способ лечения отморожений III-IV степени, включающий использование препаратов улучшающих микроциркуляцию в поврежденных тканях, отличающийся тем, что внутрибрюшинно вводят синтетический аналог простагландина E1 - альпростадил, ежедневно в дозе 0,05 мкг в течение 10 сут под визуальным и планиметрическим контролем.A method for the treatment of frostbite of the III-IV degree, including the use of drugs that improve microcirculation in damaged tissues, characterized in that the synthetic analogue of prostaglandin E 1 , alprostadil, is administered intraperitoneally daily at a dose of 0.05 μg for 10 days under visual and planimetric control.
RU2004108902/14A2004-03-262004-03-26
METHOD FOR TREATING FREEZERS OF III-IV DEGREES
RU2004108902A
(en)
Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
Pharmaceutical composition and method of treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and / or ischemic consequences
New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease